Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CARM | US
0.00
6.02%
Healthcare
Biotechnology
30/06/2024
09/03/2026
0.04
0.04
0.04
0.04
Carisma Therapeutics Inc. a biopharmaceutical company develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response and technology leverages advances in macrophage biology chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia Pennsylvania.
View LessStrength based on increasing price with high volume
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
95.8%1 month
102.9%3 months
139.0%6 months
197.3%-
-
112.50
10.44
0.06
-0.06
0.40
-
-72.61M
1.83M
1.83M
-
-126.89
-
158.30
-216.21
7.53
3.32
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.01
Range1M
0.01
Range3M
0.07
Rel. volume
1.52
Price X volume
4.50K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Dermata Therapeutics Inc. Common Stock | DRMA | Biotechnology | 1.33 | 2.01M | 6.40% | n/a | 0.00% |
| Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.24 | 1.75M | 0.00% | n/a | 6.68% |
| Plus Therapeutics Inc | PSTV | Biotechnology | 0.2952 | 1.74M | 2.25% | n/a | -45.04% |
| BioRestorative Therapies Inc | BRTX | Biotechnology | 0.232 | 1.61M | 8.97% | n/a | 0.77% |
| Lipella Pharmaceuticals Inc. Common Stock | LIPO | Biotechnology | 0.194 | 1.57M | 25.08% | n/a | 5.50% |
| Azitra Inc | AZTR | Biotechnology | 0.203 | 1.55M | 12.53% | 0.01 | 41.86% |
| ERNA | ERNA | Biotechnology | 0.283 | 1.53M | -0.70% | n/a | -577.12% |
| Kala Pharmaceuticals Inc | KALA | Biotechnology | 0.2605 | 1.43M | -6.33% | n/a | 268.29% |
| International Stem Cell Corporation | ISCO | Biotechnology | 0.1761 | 1.41M | n/a | 0.00% | |
| XORTX Therapeutics Inc. Common Stock | XRTX | Biotechnology | 0.4599 | 1.38M | -1.88% | n/a | 3.09% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.06 | 0.53 | Cheaper |
| Ent. to Revenue | 0.40 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 112.50 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 139.03 | 72.80 | Riskier |
| Debt to Equity | 10.44 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 1.83M | 3.66B | Emerging |